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Abstract
Epidemiologic studies have shown that diabetes mellitus is associated positively with increased risk of pancreatic
ductal adenocarcinoma (PDAC), and recent meta-analysis studies showed that metformin, reduces the risk of
pancreatic cancer (PC). We tested the effects of metformin on pancreatic intraepithelial neoplasia (PanIN) and
their progression to PDAC in p48Cre/+.LSL-KrasG12D/+ transgenic mice. Mice fed control diet showed 80%
and 62% incidence of PDAC in males and females, respectively. Male mice showed 20% and 26%, and female
mice showed 7% and 0% PDAC incidence with 1000- and 2000-ppm metformin treatments, respectively. Both
doses of metformin decreased pancreatic tumor weights by 34% to 49% (P < 0.03-0.001). The drug treatment
caused suppression of PanIN 3 (carcinoma in situ) lesions by 28% to 39% (P < .002) and significant inhibition
of carcinoma spread in the pancreas. The pancreatic tissue and/or serum of mice fed metformin showed a sig-
nificant inhibition of mammalian target of rapamycin (mTOR), extracellular signal-regulated kinases (ERK),
phosphorylated extracellular signal-regulated kinases (pErk), and insulin-like growth factor 1 (IGF-1) with an in-
crease in phosphorylated 5′ adenosine monophosphate kinase (pAMPK), tuberous sclerosis complex 1 (TSC1,
TSC2), C-protein and an autophagy related protein 2 (ATG2). The cancer stem cell (CSC) markers were significantly
decreased (P < 0.04-0.0002) in the pancreatic tissue. These results suggest that biologic effects of metformin
are mediated through decreased CSC markers cluster of differentiation 44 (CD44 and CD133), aldehyde
dehydrogenase isoform 1 (ALDH1), and epithelial cell adhesion molecule (EPCAM) and modulation of the mTOR
signaling pathway. Our preclinical data indicate that metformin has significant potential for use in clinical trials for
PC chemoprevention.
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Introduction
Pancreatic cancer (PC) is a devastating disease almost uniformly
lethal, with a <6% 5-year survival. The estimated incidence of PC in
the United States has increased to 42,220 new cases with more than
38,460 deaths in 2013 and is now the fourth leading cause of cancer
mortality in both men and women [1]. The Pancreatic Action Network
estimates that, by 2020, PC will become the second leading cause of
cancer-related deaths in the United States. Lack of early diagnosis and
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effective interventions are major factors in the poor prognosis and dis-
mal survival rates [2–4]. So far, a range of targeted therapies against
epidermal growth factor receptor, RAS/MAP kinase effector kinase,
and vascular endothelial growth factor has failed to improve survival
significantly in many clinical trials. The PC precursors, pancreatic
intraepithelial neoplasia (PanIN), progress slowly over many years to
the development of invasive PC [2–4]. Hence, developing preventive
strategies to delay progression of PC is currently of intense interest.
Several epidemiological studies have shown that type 2 diabetes
mellitus is positively associated with increased risk for developing PC
and worse clinical outcome [5–8]. A recent analysis of a large pooled
set of studies included in the National Cancer Institute Pancreatic
Cancer Cohort Consortium has provided strong support for a positive
association between obesity and increased risk of PC [9]. More than
80% of patients with PC have diabetes [5–9]. The interrelationship
between PC and diabetes and how diabetes affects the clinical outcome
of PC have yet to be fully elucidated. Improved understanding of the
disease mechanisms shared by diabetes and PC may be a key to devel-
opment of novel preventive strategies. Obesity, metabolic syndrome,
new-onset diabetes, and chronic pancreatitis may increase risk of PC
[10–13]; thus, patients with new-onset diabetes and/or chronic pan-
creatitis may constitute a population in whom PC can be detected
early. Metformin (1,1-dimethylbiguanide hydrochloride), the most
widely prescribed drug for treatment of type 2 diabetes worldwide, is
emerging as a potential anticancer agent. Recent meta-analysis studies
showed that metformin, an insulin-lowering agent, reduces risk of PC.
A recent study of 973 patients demonstrated that metformin treatment
was associated with a 62% reduction of risk for PC [10].
Several cancers, including PC, are characterized by aberrant activa-
tion of mammalian target of rapamycin (mTOR) [11]. Genetic and
molecular epidemiologic data strongly suggest that use of metformin
for lowering blood insulin levels and reversal of insulin resistance targets
insulin-like growth factor (IGF) signaling and modulates AMP kinase
(AMPK), which could be a useful strategy for PC prevention. In vitro
and preclinical animal models confirmed that metformin induces
AMPK activation, inhibits the Akt/mTOR pathway, and also elimi-
nates cancer stem cells (CSCs) and inhibits tumor growth [12,13].
Metformin activation of phosphorylated AMPK (pAMPK) can inhibit
mTOR activity in several ways, including directly targeting raptor,
a component of rapamycin-sensitive mTOR complex 1 [14]. Both
mTOR and AMPK control the energy status of a cell (ATP/AMP ratio)
and regulate key aspects of cell growth. Insulin/IGF receptor signaling
is mediated through the phosphatidylinositol 3-kinase/Akt/mTOR
signaling pathway [15], a key pathway in PC proliferation [16]. Al-
though epidemiological associations do not establish causation, they
provide an important line of evidence that supports the need of fur-
ther preclinical and clinical studies. Studies have shown clearly that
metformin administration inhibits the growth of human pancreatic
adenocarcinoma PANC-1 and MiaPaCa-2 tumor xenografts in vivo
in a dose-dependent manner [17]. Studies have also demonstrated
that metformin elicits a protective effect by targeting CSCs and
mTOR signaling. However, efficacy and systematic analysis of met-
formin in a preclinical model that recapitulates human PC has not
yet been evaluated.
In this study, we investigated the effects of the antidiabetic drug met-
formin on PanIN and their progression to pancreatic ductal adeno-
carcinoma (PDAC) in p48Cre/+.LSL-KrasG12D/+ transgenic mice. We
examined the impact of metformin on tumor incidence and spread
and the direct effects of metformin on mTOR signaling and on CSC
markers. Our results provide key experimental evidence to guide future
clinical investigations to establish metformin therapy in patients with PC.
Materials and Methods
Mouse Model, Diet, and Handling
The generation of p48Cre/+;LSL-KrasG12D/+ mice expressing activated
KrasG12D oncogene has been described previously [18]. All animal
research was performed under the animal protocols approved by the
University of Oklahoma Health Sciences Center Institutional Animal
Care and Use Committee. Animals were housed in ventilated cages
under standardized conditions (21°C, 60% humidity, 12-hour light/
12-hour dark cycle, 20 air changes per hour) in the University Rodent
Barrier Facility. Semi-purified modified AIN-76A diet ingredients
were purchased from Bio-Serv, Inc (Frenchtown, NJ). Metformin was
procured from the Division of Cancer Prevention, National Cancer
Institute chemoprevention drug repository. Metformin (1000 and
2000 ppm) was premixed with small quantities of casein and then
blended into the diet using a Hobart Mixer. Both control and experi-
mental diets were prepared weekly and stored in the cold room. Mice
were allowed ad libitum access to the respective diets and to automated
tap water purified by reverse osmosis. The primary antibodies used
were pAMPK, annexin V, cluster of differentiation 133 (CD133), and
C-protein from Abcam (Cambridge, MA); mTOR, CD24, CD44
(HCAM), extracellular signal-regulated kinases (ERK), phosphorylated
extracellular signal-regulated kinases (pErk), epithelial cell adhesion
molecule (EPCAM), α-tubulin, p70-S6K (serine/threonine kinase) and
insulin-like growth factor 1 (IGF-1) from Santa Cruz Biotechnology
(Santa Cruz, CA); and c-Myc and β-actin from Cell Signaling Technology
(Danvers, MA).
Breeding and Genotyping Analysis
LSL-KrasG12D/+ and p48Cre/+ mice were maintained in a C57BL/6
heterozygous genetic background. LSL-KrasG12D/+ and p48cre/+ mice
were bred, and the offspring of activated p48Cre/+.LSL-KrasG12D/+ and
C5BL/6 wild-type mice were generated at required quantities. Briefly,
genomic DNAwas isolated from tail tissue samples using the mini-prep
kit (Invitrogen, Carlsbad, CA). Polymerase chain reaction (PCR) was
performed for Kras and Cre genes using the following conditions:
denaturation at 95°C for 5 minutes, followed by 35 cycles at 95°C for
1 minute, 60°C for 1 minute, and 72°C for 1 minute. Oligonucleotide
primer sequences used were given as follows: Kras, 5′-CCTTTAC-
AAGCGCACGCAGAG-3′ (sense) and 5′-AGCTAGCCACCAT-
GGCTTGAGTAAGTCTGCA-3′ (antisense); p48Cre, 5′-ACCGT-
CAGTACGTGAGATATCTT-3′ (sense) and 5-ACCTGAAGATG-
TTCGCGATTATCT-3′ (antisense). PCR products were separated
on a 2% agarose gel. Successful recombination yields were 550- and
350-bp products for Kras and Cre genes, respectively. The genotype
of each pup was confirmed by tail DNA extraction and PCR.
Preclinical Efficacy Assay
Male and female p48Cre/+–LSL-KrasG12D/+ transgenic mice were
used in the efficacy study (Figure W1). The experimental protocol is
summarized in Figure W1. Briefly, 5-week-old mice were selected
and randomized so that average body weights in each group were equal
(n = 20-35 per group, p48Cre/+–LSL-KrasG12D/+ mice and n = 30 per
group, C57BL/6 wild-type mice) and were fed AIN-76A diet for
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1 week. At 6 weeks of age, mice were fed AIN-76A experimental diets
containing 0-, 1000-, or 2000-ppm metformin until termination of
the study (Figure W1). Mice were checked routinely for signs of weight
loss or any signs of toxicity or any abnormalities. Body weight of each
animal was measured once weekly for the first 6 weeks and then once
a month until termination (Figure W2). After 265 days (38 weeks or
∼10 months) on experimental diets, all mice at 44 weeks (∼300 days)
of age were killed by CO2 asphyxiation and necropsied; pancreata were
collected from all groups, weighed, and snap frozen in liquid nitrogen
for further analysis. Pancreata (head to tail) required for histopathologic
and immunohistochemical (IHC) evaluations to identify PanIN
lesions and PDAC and for evaluation of various molecular markers
were fixed in 10% neutral buffered formalin as previously described.
Analysis of PanIN Lesions and PDAC
Normal and tumor pancreatic tissues were fixed in 10% neutral
buffered formalin for 24 to 48 hours and then processed and embedded
in paraffin according to standard protocols. Tissue sections (4 μm) of
each pancreas stained with hematoxylin and eosin (H&E) were evalu-
ated histologically by a pathologist blinded to the experimental groups.
PanIN lesions and carcinomas were classified according to histopathol-
ogy criteria as previously described [18]. To quantify the progression of
PanIN lesions, the total number of ductal lesions and their grades were
determined. The relative proportion of each PanIN lesion grade to the
overall number of analyzed ducts was recorded for each animal. Simi-
larly, pancreatic carcinoma and normal appearing pancreatic tissue
were evaluated for all the animals.
IHC and Immunofluorescence
Five-micrometer fixed sections were incubated with primary anti-
bodies in a hybridization chamber for 1 hour at room temperature or
overnight at 4°C. The primary antibodies used were for mTOR,
pAMPK, CD24, CD44 (HCAM), EPCAM, and annexin V. Follow-
ing incubations with primary antibody, sections were incubated for
1 hour with anti-mouse or anti-rabbit secondary antibodies, as appro-
priate for each primary, then visualized with DAB and counterstained
with hematoxylin for IHC and counterstained with 4′,6-diamidino-
2-phenylindole (DAPI) for immunohistofluorescence (IHF). Slides
were observed under an Olympus microscope 1X701, and digital
computer images were recorded with an Olympus DP70 camera.
Protein Extraction and Western Blot Assay
Pancreata harvested from mice fed diets with or without metformin
were homogenized and lysed in ice-cold lysis buffer. After a brief
Figure 1. (A and B) Effect of metformin on pancreas weights at the termination of the experiment in male (A) and female (B) mice. Both
doses of metformin significantly reduced the pancreatic tumor weights. (C and D) Effect of metformin on the incidence (percentage of mice
with carcinomas) of PDAC in male (C) and female (D) mice. Effect of metformin on survival and mortality of male (E) and female (F) mice.
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vortexing, the lysates were collected by centrifugation at 12,000g for
15 minutes at 4°C, and protein concentrations were measured with the
Bio-Rad Protein Assay reagent (Bio-Rad, Hercules, CA). An aliquot
(50 μg of protein per lane) of the total protein was separated with
10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis and
transferred to nitrocellulose membranes. After blocking with 5% milk
powder, membranes were probed for expression of ERK, pERK,
c-Myc, CD133, p70-S6, IGF-1, C-protein, β-actin, and α-tubulin
in hybridizing solution (1:500, in TBS–Tween 20 solution) using
the respective primary antibodies and then probed with the appropriate
HRP-conjugated secondary antibodies. Detection was performed using
the SuperSignal West Pico Chemiluminescence procedure (Pierce,
Rockford, IL). All the Western blot experiments were repeated two
times with six untreated samples, six 1000-ppm metformin-treated
samples, and six 2000-ppmmetformin-treated samples. ImageJ software
was used for quantification of the blots.
Quantitative Real-Time PCR Analysis
Total RNA from tumor samples was extracted using RNA Kit for
isolation of total cellular RNA (Invitrogen) as per the manufacturer’s
instructions. Equal quantities of DNA-free RNA were used for re-
verse transcription (RT) reactions for making cDNA using SuperScript
reverse transcriptase (Invitrogen). The real-time PCR was carried
out in a 25-ml reaction volume using 3 ml of a 1:10 cDNA dilu-
tion containing SYBR Green master mix (BioRad) and primers for
mTOR, Rheb, tuberous sclerosis complex 1 (TSC1), TSC2, cyclin
D1, autophagy related protein 2 (ATG2), caspase-3, Bax, Bcl-2,
CD44, EPCAM, CD133, aldehyde dehydrogenase 1 (ALDH1), and
Dclk1 as previously described [13,19–21]. All PCRs were done in a
Bio-Rad iCycler iQ real-time PCR detection system. The fluorescence
threshold values (C t) were calculated. Relative mRNA levels were
assessed by standardization to glyceraldehyde phosphate dehydro-
genase. Results are expressed as a fold difference in gene expression.
Statistical Analysis
The data are presented as means ± SE. Differences in body weights
were analyzed by analysis of variance. Statistical differences between
control and treated groups were evaluated using Fisher’s exact test
for PDAC incidence, and unpaired t test with Welch’s correction
was used for PanIN and PDAC lesions. Differences between groups
are considered significant at P < .05.
Results
General Health of Animals
Transgenic p48Cre/+;LSL-KrasG12D/+ mice fed AIN-76A or met-
formin diets had steady body weight gains. As shown in Figure W2,
there was no significant difference in body weight in the mice fed
either AIN-76A or AIN-76A diet supplemented with either 1000-
or 2000-ppm metformin. None of the animals fed the metformin diets
exhibited any observable toxicity or any gross morphologic changes to
liver, spleen, kidney, or lung.
Figure 2. (A and B) Effect of metformin on the PanIN multiplicity (means ± SE; A—male, B—female). (C and D) Percentage of carcinoma
spread per pancreas (C—male, D—female; 0—0 ppm, LD—1000 ppm, HD—2000 ppm). (E and F) Effect of metformin on normal pancreas
(E—male, F—female). The data in the panels were analyzed by unpaired t test with Welch’s correction; values are considered statistically
significant at P < .05.
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Effect of Metformin Diet on Pancreas Weight and
PDAC Incidence in Transgenic Mice
Pancreatic weight is a simple marker to determine the progression of
tumor. In the C57BL/6J wild-type mice, the average pancreas weight
was 0.29 ± 0.01 g in male mice and 0.28 ± 0.05 g in female mice.
A significant increase in pancreas weight was observed in p48Cre/+;
LSL-KrasG12D/+ mice compared with wild-type mice (1.45 ± 0.13 g
in male mice and 1.1 ± 0.13 g in female mice, P < .0001). As sum-
marized in Figure 1, A and B, the effect of metformin on the weight
of pancreatic tumor revealed a significant difference between treat-
ment groups in p48Cre/+;LSL-KrasG12D/+ mice. In transgenic mice fed
1000- or 2000-ppmmetformin, the pancreas weights were 0.88 ± 0.14
and 0.95 ± 0.09 g, respectively, in males and 0.61 ± 0.04 and 0.56 ±
0.05 in females. In addition, no significant differences in the body
weights were observed between wild-type mice and p48Cre/+;LSL-
KrasG12D/+ mice fed with either AIN-76A or metformin-supplemented
diets (Figure W2).
Extensive histopathologic analysis of the pancreas using H&E-
stained slides revealed no microscopic pathologic alterations in wild-
type mice fed either AIN-76A or metformin-supplemented diets
(Figure 1, E and F ). In contrast, AIN-76A diet–fed male and female
p48Cre/+;LSL-KrasG12D/+ mice demonstrated 80% and 62% incidence
of PDAC (percentage of mice with PDAC), respectively (Figure 1,
C–F , and W3). Metformin treatment at 1000 and 2000 ppm sig-
nificantly inhibited PDAC incidence by 67% to 80% in males and
by up to 93% to 100% in female transgenic mice (Figure 1, C–F).
Inhibition of PanIN Lesion Progression and Carcinoma
Spread by Metformin
Histologic analysis showed that none of the wild-type mice
had PanIN lesions, whereas 100% penetrance of PanIN lesions
was observed in the transgenic mice fed AIN-76A or metformin-
supplemented diets. The numbers of PanIN 1, 2, and 3 lesions in male
transgenic mice fed AIN-76A diet were (mean ± SE) 177 ± 36, 155 ±
15, and 169 ± 17, respectively; in the mice fed 1000-ppm metformin,
PanIN 1, 2, and 3 numbers were 368 ± 59, 193 ± 28, and 103 ± 13,
respectively; and in mice fed 2000-ppm metformin, they were 375 ±
13, 182 ± 18 and 122 ± 37, respectively (Figure 2A). The numbers of
PanIN 1, 2, and 3 lesions in female transgenic mice fed AIN-76A diet
were 193 ± 33, 150 ± 20, and 124 ± 18, respectively; in the mice fed
1000-ppmmetformin, the numbers were 357 ± 36, 155 ± 20, and 79 ±
11; and in mice fed 2000-ppm metformin, they were 289 ± 47, 169 ±
15, and 185 ± 22, respectively (Figure 2B). The number of PanIN
Figure 3. Effect of metformin on mTOR and pAMPK in pancreatic tumors. IHC and immunofluorescence analyses were performed with
paraffin-embedded and microsectioned pancreatic tissues as described in the Materials and Methods section. A significantly decreased
expression of mTOR and an increased pAMPK expression were seen with metformin treatment.
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3 lesions or carcinoma in situ was suppressed by 28% to 39% in the
metformin-treated groups (Figure 2, A and B). A statistically signifi-
cant increase in the number of PanIN 1 and 2 lesions was observed
in metformin-supplemented mouse pancreas, suggesting a potential
blockade of further progression of these lesions to carcinoma in situ
and PDAC. Pancreata of transgenic mice fed AIN-76A diet showed
a 43.6 ± 7.5% (male; Figure 2C) and 41 ± 7.5% (female; Figure 2D)
spread of PDAC within the pancreas. Most importantly, the carcinoma
spread within the pancreas was significantly inhibited (>95%, P <
.0001; Figure 2, C andD) by both doses of metformin in both genders
of transgenic mice. In support of the above, we observed that up to
29% of the pancreas from mice treated with metformin was normal
appearing (i.e., free from PanIN lesions and carcinoma), whereas up
to 9% was found to be normally appearing in the untreated transgenic
mice (Figure 2, E and F).
Modulation of mTOR/pAMPK Signaling by Metformin
Activation of the mTOR/pAMPK pathway was measured by IHC
and IHF in PanIN lesions and PDAC. As shown in Figure 3, markedly
decreased mTOR staining with a dramatic increase in pAMPK
was observed in PanIN lesions in p48Cre/+;LSL-KrasG12D/+ mice
fed metformin-supplemented diets compared with the pancreatic
tissues from mice fed AIN-76A diet alone. The expression of mTOR
and its related signaling molecules in the pancreas was further analyzed
using real-time quantitative PCR and/or Western blot assays. Snap
frozen pancreatic tissues were analyzed for the fold change in mRNA
expression of mTOR, Rheb, cyclin D1, ATG2, and the tumor sup-
pressors TSC1 and TSC2. Total RNA was isolated and reverse tran-
scribed into cDNA and quantified with a real-time PCR assay. As
shown in Figure 4, A to F , compared with AIN-76A–fed p48Cre/+;
LSL-KrasG12D/+ mice, the pancreatic tissues of metformin-fed trans-
genic mice showed a significantly decreased expression of mTOR,
Rheb, and cyclin D1 (Figure 4, A, B, and E ) with an increase in
TSC1, TSC2, and ATG2 (Figure 4, C , D, and F ; P < .05). More than
a two-fold decrease of mTOR, Rheb, and cyclin D1 mRNA expression
was found in mice fed the diet containing metformin in comparison
with AIN-76A diet–fed mice (P < .05). More than a three-fold increase
in mRNA expression was found for TSC1, TSC2, and ATG2 in mice
fed a diet containing metformin.
Western blot assays were performed to estimate the expression
of ERK, pERK, c-Myc, p70-S6, and CD133 proteins in the pan-
creatic tissues and of IGF-1 and C-protein in serum. As shown in
Figure 4G , there was an increase in the ERK levels with a significant
decrease in pERK and its downstream markers in pancreatic tissues
of mice treated with metformin-supplemented diets as compared with
mice fed AIN-76A diet alone. The levels of IGF-1 and C-proteins in
serum were decreased in mice treated with lower doses of metformin-
supplemented diets (Figure 4H ). These results are consistent with the
effects of metformin on molecular signaling in earlier reports.
Inhibition of Cancer Stem Cell Markers by Metformin
To determine the expression of CSC markers in the pancreatic
tissues of the transgenic mice, CD24, CD44, EPCAM, CD133,
ALDH1, and DclK1 were analyzed using both IHF and real-time
Figure 4. (A–F) Effect of metformin on the expression of mRNA for mTOR, Rheb, TSC1, TSC2, cyclin D1, and ATG2, as determined with
quantitative real-time PCR. (G) Effect of metformin on the expression of ERK, pERK, cMYC, CD133, and p70-S6 proteins in PDAC. (H) Effect
of metformin on IGF-1 and C-protein in the serum. Protein expression was analyzed by Western blot analysis as described in the text.
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PCR approaches. IHF staining showed that PanIN lesions were posi-
tively labeled by both CD24 and CD44, which were co-localized
in the pancreas of p48Cre/+;LSL-KrasG12D/+ mice fed AIN-76A
diet alone (Figure 5A). Markedly decreased numbers of CD24 and
CD44 and their co-localization were observed in lesions of mice fed
a metformin-supplemented diet (Figure 5A). To examine the effect
of metformin on the mRNA expression of CSC marker genes in
pancreatic tissues, we measured the relative mRNA levels of the
markers by quantitative RT-PCR. We found that metformin sig-
nificantly decreased the expressions of CD24, CD44, EPCAM,
CD133, and ALDH1 mRNA in pancreatic tissues of transgenic mice;
there was a nonsignificant decrease in DclK1. These results suggest
that the inhibition of tumor progression may be associated with the
down-regulation of CSC markers (Figure 5, B–F) and are consistent
with our in vivo tumor inhibition findings.
Metformin Induces Apoptosis
We conducted fluorescence imaging microscopy to examine the
effect of metformin on the expression of CSC surface biomarkers
along with the apoptosis marker annexin V. As shown in Figure 6,
the staining intensity of annexin V (green) was very low, whereas
CD44 (red) was significantly higher in the PanIN lesions of mice
fed AIN-76A diet. In contrast, we found a substantial increase in
annexin V in lesions of treated pancreas, suggesting that metformin
induces apoptosis in the lesions. Moreover, the CD44- and EPCAM-
stained cells showed greater annexin V staining intensity in the
metformin-treated pancreatic lesions compared with those in mice
fed AIN-76A diet. These results demonstrate that metformin induces
apoptosis and greatly decreases CSC markers CD44 and EPCAM
(Figure 6). To further determine the effects of metformin on mRNA
of apoptotic markers in pancreatic tissues, we measured relative
mRNA levels of markers by quantitative RT-PCR. We found that
metformin significantly increased the expressions of caspase-3 and
Bax mRNA in pancreatic tissues of lower dose–treated transgenic
mice; there was a nonsignificant increase in Bax with the higher dose
(Figure 6). We observed a significant decrease in anti-apoptotic
marker Bcl-2 on treatment with the lower dose of metformin (Fig-
ure 6). These results suggest that the inhibition of tumor progression
may be associated with the increase in apoptosis and are consistent
with our in vivo tumor inhibition findings.
Discussion
Recent meta-analysis determined that the antidiabetic drug metformin
reduces the incidence of overall cancers including liver, pancreatic,
Figure 5. Effect of metformin on CSC markers in pancreatic tumors. (A) Immunofluorescence analysis for CD24 and CD44 was per-
formed on paraffin-embedded and microsectioned pancreatic tissues as described in the Materials and Methods section. A significantly
decreased expression of CD24, CD44, and CD44/CD244 ratio was seen with metformin treatment. (B–F) Effect of metformin on the
expression of mRNA for the CSC markers CD44, EPCAM, CD133, ALDH1, and DclK1, as determined with quantitative real-time PCR.
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colorectal, and breast cancers as well as the mortality from these can-
cers [7,9]. Several observational and preclinical studies have shown that
metformin may modify the risk for PC. The anticancer effects of met-
formin have also been demonstrated in many in vitro studies. In a ret-
rospective study of patients with PC and preexisting diabetes, Sadeghi
et al. observed that the overall survival duration was 4.1 months longer
and the 1-year survival rate was 18.8% higher in patients treated with
metformin than in those not treated with metformin. The beneficial
effects of metformin were seen in all disease stages but were statistically
significant only in patients with nonmetastatic disease. Metformin
use was also associated with a 32% reduction in the risk of death
[22]. These data provide strong supporting evidence that metformin
has the potential to be used as a chemopreventive agent for treating
high-risk individuals and patients with initial stages of PC. Studies
Figure 6. Effect of metformin on apoptosis and CSC markers. Dual immunofluorescence analysis for annexin V/CD44 (green/red) and
annexin V/EPCAM (green/red) was performed with paraffin-embedded and microsectioned pancreatic tissues as described in the
Materials and Methods section. A significant decrease in CSC markers (CD44 and EPCAM) was associated with an increased apoptosis
(annexin V—green) on metformin treatment. Effect of metformin on the expression of mRNA for the apoptotic markers caspase-3 and
Bax and anti-apoptotic marker Bcl-2 as determined with quantitative real-time PCR.
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conducted in various preclinical animal tumor models [13,23–25] and
in vitro cancer cell lines [26–30] have shown that metformin inhibits
tumor development and growth of cancer cells. While most previous
in vitro studies used very high concentrations of metformin, the clini-
cal significance of the inhibitory effects obtained using higher doses
of metformin has been questioned. In PC studies, metformin has
been shown to inhibit the growth of xenografts in nude mice through
disruption of cross-talk between the insulin receptor and G protein–
coupled receptors [15–17,31,32]. In a high-fat diet and carcinogen-
induced pancreatic tumor model, metformin completely prevented
the development of tumors [33].
To understand the mechanism for the anticancer effects of metfor-
min, it is important to elucidate whether this antidiabetic drug can
exert direct effects on in vivo transgenic animal models of PC that
recapitulate the stepwise progression of precursor lesions to carcinoma
as seen in humans. We have used a dose of metformin slightly higher
than that used clinically to treat diabetes and a dose double that to
evaluate its potential against prevention of PC progression in the
p48Cre/+;LSL-KrasG12D/+ mouse model. This model is well established
and extensively studied by us and others for chemoprevention of PC
[4,18–20,34–37]. In the present study, we have demonstrated the
chemopreventive effects of metformin against formation and progres-
sion of PanIN lesions to carcinoma. Recently, pancreatic xenograft
studies have shown that metformin at 200 mg/kg body weight
(∼1000 ppm in the diet) had maximal tumor suppression effects
and caused a pronounced decrease in S6 and ERK [17]. We observed
that metformin at 1000 ppm, i.e., ∼200 mg/kg body weight, showed
80% and 93% inhibition of PDAC incidence in male and female
transgenic mice, respectively. However, we failed to observe a dose
response effect with 2000-ppm treatment in male mice. A 74% sup-
pression of PDAC incidence was seen in male mice treated with the
higher dose of metformin, whereas no carcinoma was observed in
female mice treated with this dose. These results are in line with the
recent reports on the effective doses of metformin for PC. Further,
Quinn et al. recently showed that metformin at 5 mg/ml in drinking
water (equivalent to ∼5000 ppm in the diet) significantly inhibited
lung tumorigenesis [38].
Consistent with the above PDAC incidence data, metformin-
treated mice had a significant delay in progression of PanIN lesions
versus untreated animals. A significant accumulation in the number
of PanIN 1 and 2 lesions was observed in the metformin-treated
pancreas compared with untreated, suggesting that many of the
PanIN 1 and 2 lesions did not further progress into carcinoma
in situ and PDAC. PanIN 3 lesions were reduced by 29% to 38%
in the metformin-treated groups, clearly suggesting a blockade of
the progression of precursor lesions to carcinoma. More than 95%
inhibition of carcinoma spread was observed in male and female
transgenic mice treated with metformin. Notably, the response
rate is better in female mice compared to male mice because the
transgenic male mice but not female mice with Kras activation de-
velop much more aggressive PDAC (Figure 1, C and D). To our
knowledge, this is the first report showing that the genetically pre-
determined progression of PanIN lesions to carcinoma in the condi-
tional KrasG12D/+ mouse model can be attenuated by the antidiabetic
drug metformin.
The ability of mutant oncogenic Kras to induce malignant trans-
formation probably depends on its ability to persistently activate
downstream effectors. We therefore reasoned that the ability of met-
formin to delay PanIN progression and inhibit carcinoma may be
mediated, at least in part, by interfering with the Kras oncogenic
pathways. Mechanistically, the metabolic regulation and antitumor
activity of metformin are mediated mainly through activation of
the AMPK signaling pathway. Metformin reduces mitochondrial
ATP production by inhibiting complex I of oxidative phosphoryla-
tion [8], which results in the activation of the AMPK signaling path-
way and, in turn, downregulates the mTOR pathway. Accumulating
evidence from in vitro and in vivo studies has shown that metfor-
min exerts its antitumor effect by targeting multiple signaling path-
ways such as AMPK/mTOR, anti-inflammatory pathways, cell cycle/
apoptosis, insulin/IGF-1R, and angiogenesis and by targeting CSCs
in cancers. Some studies also found that metformin could inhibit
directly the mTOR pathway, independent of AMPK activation
[39,40]. We determined the effects of metformin on mTOR and
pAMPK signaling, CSC markers, and apoptosis. Our data suggest that
metformin significantly regulates mTOR and pAMPK in pancreatic
carcinogenesis. Our observation is consistent with other recent reports
in which metformin disrupts mTOR, IGF-1, and CSC signaling
pathways and prevents tumor growth [8,12,13,16,17,31,32,38]. We
observed that metformin significantly reduces mTOR and its signal-
ing molecules Rheb, pERK, c-Myc, p70-S6, and cyclin D1. We also
found that metformin increases pAMPK and the tumor suppressors
TSC1 and TSC2.
Recently, metformin has been reported to target CSCs selectively
and to enhance the efficacy of chemotherapeutic drugs in blocking
tumor growth [12]. CSCs are believed to be responsible for initia-
tion of the malignant growth and metastasis and possess the ability
to self-renew and give rise to differentiated tumor cells, which con-
tribute to resistance to conventional therapeutics. Therefore, target-
ing CSCs may provide a novel strategy for cancer inhibition with
better outcome. A detailed evaluation revealed that metformin did
inhibit CSC markers in the PanIN lesions of the pancreas com-
pared with nontreatment. Metformin inhibited the CSC markers
CD24, CD44, EPCAM, CD133, ALDH1, and DclK1 in the pres-
ent study. These markers have been identified as CSC markers
in PC, and metformin was found to target these CSC markers in
other cancers as well, thereby preventing tumor growth [8,12,13,20].
Metformin may also exert some of its antitumor activity through
regulating lipid metabolism, endothelial function, immune functions
[41–44], apoptosis, and insulin signaling. The analysis of serum
revealed that metformin, at the lower dose, profoundly inhibits IGF-1
and C-protein, suggesting that these proteins could serve as biomarkers
in individuals treated with metformin for chemoprevention of PC.
A previously reported case-controlled study of PC showed that a
2-year duration of metformin use was associated with reduced risk of
PC [10], which suggests that metformin may not only prevent tumor
development by inhibiting cell transformation and proliferation
during the early stages of tumorigenesis but that it may also delay
cancer progression [44]. Findings from the current study are con-
sistent with other previous observations that support the use of
metformin as a potential chemoprevention agent for PC and as a
supplement for chemotherapy. Further transgenic mouse xenograft
studies involving human PC cells along with improved imaging tech-
nologies [36,45,46] would strengthen the need for use of metformin
for chemoprevention and treatment. Considering the high prevalence
of diabetes in patients with PC and the lack of effective treatment
strategies for this deadly disease, prospective studies should be con-
ducted quickly to confirm the chemopreventive benefits of metformin
use in patients with diabetes and PC.
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In conclusion, our study shows that dietary metformin delayed the
progression of PanIN lesions and ultimately decreased the incidence
of invasive PC in p48Cre/+;LSL-KrasG12D/+ mice, suggesting that the
anticancer action could be mediated, at least in part, through a direct
effect on mTOR signaling and CSCs. One of the major concerns in
chemoprevention strategies is potential toxicity associated with pro-
longed treatment. We show here that the widely used antidiabetic drug
metformin targets PC cells along with cells positive for the markers of
CSCs and mTOR signaling in oncogenic Kras-transformed pancreatic
cells, inducing apoptosis without toxicity, and thus, its use may provide
a new chemoprevention approach. Translational studies in early-
phase clinical trials will validate the biomarkers of metformin that
were observed in this study.
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Figure W1. Experimental design for evaluation of metformin efficacy in PC prevention in male and female p48Cre/+–LSL-KrasG12D/+ mice.
At 6 weeks of age, groups (20-35 per group activated p48Cre/+–LSL-KrasG12D/+ or 12 per group wild-type) of mice were fed AIN-76A diets
containing 0-, 1000-, or 2000-ppm metformin continuously for 38 weeks, and each pancreas was evaluated histopathologically for marker
expressions as described in the text.
Figure W2. (A and B) Effect of metformin on body weights (means ± SE) at the termination of the experiment. No statistically significant
difference was observed between control and metformin-treated p48Cre/+–LSL-KrasG12D/+ or wild-type mice.
Figure W3. Histopathologic analysis of untreated and metformin-treated pancreata using H&E staining. Untreated pancreata show poorly
differentiated adenocarcinoma with some of the cells invading the stroma (left panel). Pancreata treated with 1000- and 2000-ppmmetformin
show PanIN lesions (middle and right panels).
